Gefitinib resensitization after a TKI-free interval in osimertinib resistant non-small cell lung cancer: A glimpse of hope in time of crisis?
P Muscolino, C Scimone, E Sapuppo, V Micali… - Clinical Lung Cancer, 2024 - Elsevier
Over the last few years osimertinib has emerged as the standard of care for first line therapy
of advanced non-small cell lung cancer (NSCLC) patients harboring common Epidermal …
of advanced non-small cell lung cancer (NSCLC) patients harboring common Epidermal …
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM …
E Martinelli, D Ciardiello, G Martini, S Napolitano… - Clinical Drug …, 2024 - Springer
Background CAVE is a single arm, Phase 2 trial, that demonstrated anti-tumor activity of
cetuximab rechallenge plus avelumab in patients with RAS wild type (wt) metastatic …
cetuximab rechallenge plus avelumab in patients with RAS wild type (wt) metastatic …
[HTML][HTML] The role of liquid biopsy as a catalyst for sustained progress in precision oncology–Perspective of the young committee of the international society of liquid …
Over the past three decades, precision medicine has revolutionized oncology. At the
forefront of this revolution has been the continuous expansion of liquid biopsy and its …
forefront of this revolution has been the continuous expansion of liquid biopsy and its …